Acute myeloid leukemia (AML) is an aggressive blood cancer caused by a plethora of genetic mutations acquired throughout one’s lifetime. One of these genes, the tumor suppressor gene TP53, plays a crucialRead More…
Immunotherapy strategies aim to utilize the patient’s own immune system cells to eliminate tumor cells. CAR-T cell therapy is an effective treatment for human blood cancers. In France, approximately 35,000 people areRead More…
Since the world’s first chimeric antigen receptor (CAR)-T cell therapy was approved for marketing in 2017, the Food and Drug Administration (FDA) has approved a total of six CAR-T cell therapies toRead More…
The success of CAR T cells in treating hematologic malignancies has provided impetus for the development of CAR T therapies in solid tumors. The biggest obstacle to the development of CAR TRead More…
Chimeric antigen receptor T-cell (CAR-T) immunotherapy targeting CD19 has achieved surprising results in the treatment of malignant hematological tumors such as relapsed/refractory acute lymphoblastic leukemia (ALL). Clinical trial data show that theRead More…
In a new study, researchers from Massachusetts General Hospital find that the interferon gamma receptor (IFNγR) signaling pathway is critical for glioblastoma susceptibility to CAR-T cell immunotherapy . The same phenomenon hasRead More…
In a new preclinical study, researchers from Weill Cornell Medicine found that genetically engineered T cells successfully targeted specific cancer cells that may lead to relapse in acute myeloid leukemia (AML), andRead More…
CAR-T (chimeric-antigen receptor T-cell immunotherapy) has significant efficacy in the treatment of acute leukemia and non-Hodgkin’s lymphoma, and is considered to be one of the most promising tumor treatments. In recent years,Read More…
In this March, Bristol-Myers Squibb and Bluebird Bio announced that their CAR-T cell therapy idecabtagene vicleucel (Abecma) targeting B cell maturation antigen (BCMA) has been approved for the treatment of multiple myeloma,Read More…
Adoptive immunotherapy is a transformational therapy in hematology. One of the most representative adoptive immunotherapies is chimeric antigen receptor (CAR) T cell therapy. It expresses and synthesizes CAR on T cells byRead More…